Latest Updates on Health Care Sector: Special Research on bluebird bio, Brainstorm, CASI Pharmaceuticals, Celladon, and Cellular Dynamics
NEW YORK, February 16, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including bluebird bio (NASDAQ: BLUE), Brainstorm (NASDAQ: BCLI), CASI Pharmaceuticals (NASDAQ: CASI), Celladon (NASDAQ: CLDN), and Cellular Dynamics (NASDAQ: ICEL). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
BLUE Research Report: ( http://get.analystsreview.com/pdf/?c=bluebird%20bio&d=16-Feb-2015&s=BLUE ),
BCLI Research Report: ( http://get.analystsreview.com/pdf/?c=Brainstorm&d=16-Feb-2015&s=BCLI ),
CASI Research Report: ( http://get.analystsreview.com/pdf/?c=CASI%20Pharmaceuticals&d=16-Feb-2015&s=CASI ),
CLDN Research Report: ( http://get.analystsreview.com/pdf/?c=Celladon&d=16-Feb-2015&s=CLDN ),
ICEL Research Report: ( http://get.analystsreview.com/pdf/?c=Cellular%20Dynamics&d=16-Feb-2015&s=ICEL ).
============
--
Analyst Update: Breakthrough Designation, Trial Updates, Outlook, Stock Options Grant, and Collaboration
Reviewed by: Rohit Tuli, CFA®
The U.S. stocks closed higher on Friday with S&P 500 hitting an intraday record and the Dow Jones Industrial Average reaching its highest point so far this year. The Dow industrials added 46.97 points, or 0.26%, to 18019.35. The S&P 500 rose 8.51 points, or 0.41%, to 2096.99, and the Nasdaq Composite gained 36.22 points, or 0.75%, to 4893.84. The markets got a boost on hopes of a deal between Greece and its creditors. The continued redound in oil prices as well as strong economic data out of Europe also helped the markets in the rally. European markets also rose, driven by the Friday release of German data that showed the country's economy had grown in 2014's fourth quarter at a better-than-expected rate. Asia stocks mostly closed higher on Friday, following a global advance overnight, supported by reports of a new cease-fire agreement between Russia and Ukraine, Sweden's surprise move to cut its main rate into negative territory, and Greece agreeing to talks over its debt problems.
bluebird bio, Inc. (bluebird bio) announced that its LentiGlobin® BB305 Drug Product for the treatment of transfusion-dependent patients with beta-thalassemia major has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).
Brainstorm Cell Therapeutics Inc. (Brainstorm) announced that the Data and Safety Monitoring Board (DSMB) has identified "no concerns" in the Company's ongoing phase 2 clinical trial of NurOwn™ in amyotrophic lateral sclerosis (ALS), paving way for the study to continue as planned.
CASI Pharmaceuticals, Inc. (CASI Pharmaceuticals), a biopharmaceutical firm with a primary commercial focus on China, announced its anticipated 2015 milestones which, among many others, include NDA filing of ENMD-2076 in the first-line treatment of fibrolamellar carcinoma (FLC).
Celladon Corporation (Celladon), a clinical-stage biotechnology company, announced that the Compensation Committee of the Company's Board of Directors has approved the grant of inducement stock options to two new employees, which allows them to purchase a total of 13,500 shares of common stock.
Cellular Dynamics International, Inc. (Cellular Dynamics) has entered into research collaboration with Cord Blood Registry (CBR) to reprogram newborn stem cells from both umbilical cord blood and umbilical cord tissue collected, processed and cryopreserved under CBR's protocols into induced pluripotent stem cells (iPSCs) using Cellular Dynamics's proprietary methods.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article